Longeveron Inc - Ordinary Shares - Class A
LGVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.46M
Close$
$-0.23
137.1% downside
Current Fair Value
137.1% downsideOvervalued by 137.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.46 Million |
|---|---|
| Enterprise Value | $-1,452,262.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.29 |
| Beta | -0.36 |
| Outstanding Shares | 24,786,282 |
Return
| Return on Equity | -139.95% |
|---|---|
| Return on Assets | -105.75% |
| Return on Invested Capital | -135.67% |
Valuation & Multiples
| P/E Ratio | -0.59 |
|---|---|
| PEG | 10.7 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.19 |
| Enterprise Value to EBIT | 0.06 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.59 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$326,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.94%▲ 4.37% |
|---|---|
| Total Invested | $2.37M▲ 355.07% |
| Investors Holding | 30▲ 1.00% |
ESG Score
No data
About Longeveron Inc
26 employeeslongeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as...